FIG.1



(1) (2) (3) (4) (5)
M
S P S P S P S P S P
97.0
66.0
45.0
30.0
20.0
a
b
(1) NOT ADDED
(2) 10% GLYCEROL
(3) (2)+Arg
(4) (2)+dNTP
(5) (2)+Arg+dNTP

FIG.2



dA dT dC dG dNTP
S P S P S P S P S P
M
kDa
97.0
66.0
45.0
30.0
20.1
14.4

FIG.3



GTP
dGTP
2
10
50mM
2
10
50mM
kDa
M
S P S P S P
S P S P S P
M
kDa
97.0
66.0
45.0
30.0
20.1
14.4
97.0
66.0
45.0
30.0
20.1
14.4

FIG.4



GMP
GTP
10
2
0.5
10
2
0.5mM
S P S P S P S P S P S P
M
kDa
97.0
66.0
45.0
30.0
20.1

FIG.5




FIG.6



AFTER DIALYSIS AT pH 7.4
AFTER DIALYSIS AT pH 8.0
(-)
UMP
UMP
S
P
S
P
S
P
M
kDa
97.0
66.0
45.0
30.0
20.1

FIG.7

ANALYSIS OF MART-1 ANTIGEN PRODUCED BY HUMAN MELANOMA




FIG.8

RECOVERY STATE OF MART-1
WHEN MEWO INSOLUBLE FRACTION WAS SOLUBILIZED




FIG.9



BEFORE DIALYSIS
AFTER DIALYSIS
FREEZING AND THAWING
-
+
-
+
M
S
P
S
P
S
P
S
P
S
P
S
P
kDa
97.0
66.0
45.0
30.0
20.1
14.4

FIG.10



BEFORE DIALYSIS
AFTER DIALYSIS
FREEZING AND THAWING
-
+
-
+
M
S
P
S
P
S
P
S
P
S
P
S
P
kDa
97.0
66.0
45.0
30.0
20.1
14.4

FIG.11



BEFORE DIALYSIS
AFTER DIALYSIS
FREEZING AND THAWING
-
+
-
+
M
S
P
S
P
S
P
S
P
S
P
S
P
kDa
97.0
66.0
45.0
30.0
20.1
14.4

FIG.12



a)
b)
CD11c
CD11b
CD86
CD80
B1
39.1%
B2
43.2%
B3
9.7%
B4
8.0%
C1
8.6%
C2
72.8%
C3
18.4%
C4
0.1%

FIG.13




CONFIRMATION OF CTL INDUCTION ABILITY BY TETRAMER ANALYSIS
NEGATIVE CONTROL GROUP
PEPTIDE
T(U)
T(G)
0.0%
2.4%
2.3%
1.5%
0.3%
0.1%
0.3%
0.3%
TRP2
OVA
CD8

FIG.14

CYTOTOXIC ACTIVITY AGAINST B16 CYTOTOXIC MELANOMA (%)

a)



b)

